The United States Accounted for 50% of the World's Alimentary/Metabolic Drugs Market in 2005.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c37789) has announced the addition of the Espicom Business Intelligence Introduction Espicom Business Intelligence is a publisher of independent and impartial information and analysis services focusing on the pharmaceutical and medical device markets. Ltd report: New Drug Futures: Alimentary/Metabolic Chapter to their offering. This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the alimentary/metabolic sector. The report includes unique sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. by major product. The alimentary/metabolic market is the third largest therapeutic category by sales and generated nearly US$51.3bn (+4% YoY) in 2005. This market spans the sale of a broad range of drugs including; anti-ulcerants (around 34%), drugs for the treatment of gastro-oesophageal reflux disease, anti-diabetics (around 23% of the market) and anti-obesity drugs (around 2%). Sales grew slowly throughout the world with over 50% derived in the US, 25% in Europe and 16% in Japan. ANTI-ULCERANT MARKET The anti-ulcerant class totalled US$17.3 billion in 2005 (+1% YoY) and represented 3.4% of global pharmaceutical sales (estimated to be US$600 billion in 2005). The largest segment of the anti-ulcerant market were the proton pump inhibitors Proton Pump Inhibitors Definition The proton pump inhibitors are a group of drugs that reduce the secretion of gastric (stomach) acid. They act by binding with the enzyme H+, K(+)-ATPase, hydrogen/potassium adenosine triphosphatase (PPIs), which accounted for around 75% of global anti-ulcerant sales, or US$13 billion in 2005. However, the sale of PPIs has stagnated due to the patent expiry of AstraZeneca's omeprazole omeprazole /omep·ra·zole/ (o-mep´ra-zol) an inhibitor of gastric acid secretion used in the treatment of dyspepsia , gastroesophageal reflux disease, disorders of gastric hypersecretion, and peptic ulcer, including that associated with and its subsequent availability over-the-counter. This has been partially offset by the sale of Nexium, AstraZeneca's second-generation PPI (1) (Pixels Per Inch) The measurement of the resolution of a monitor or scanner. For example, a monitor that is 16 inches wide and displays 1600 pixels across its width would have a resolution of 100 ppi (1600 divided by 16). , which became the third best selling drug in 2005 and generated global sales of US$4.6 billion, equivalent to 1% of the global pharmaceutical market. DIABETES MARKET We estimate the market for anti-diabetic drugs in 2005 was worth around US$11.8 billion (around 23% of alimentary/metabolic sales), an increase of 12% year on year. Oral anti-diabetic agents accounted for over 60% of sales (US$7 billion) versus injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. insulin (US$4.6 billion). However, the revenue growth of oral anti-diabetic agents continues to slow (+5% YoY) due to the patent expiry of leading brands such as Glucophage, Glucophage XR and Glucovance and a slow down in prescription demand. Revenue growth forecasts have been driven by the sales of two of the largest drug classes, namely glitazones (monotherapy/combinations) and insulin, which continue to deliver high growth of 15% and 20% respectively. OBESITY MARKET The market for weight-loss drugs in the US, Europe, and Japan totalled around US$800 million in 2005. However, this market still offers huge opportunity for the development of novel, well-tolerated agents. The global anti-obesity market is forecast to reach sales of over US$2 billion by 2010. Answering key business questions Based on lansoprazole, TAK-390MR employs a modified- release technology for the treatment of acid-related conditions. What are the clinical benefits and what strategic role does this play in Takeda's future? Novartis' LAF-23 could be the first DDP-IV inhibitor to reach the market and could be used as 1st-line therapy or in combination with existing treatments. Long-term safety issues remain, but what % of the market could it command? This chapter covers: Current Market Size Addressable Reachable. When something is addressable, it can be identified and manipulated independently of its surroundings. For example, screen pixels and RAM memory are addressable. Each of the screen's picture elements can be individually turned on and off, and each of the memory's bytes can be Patient Population Current Treatments Sales Drivers Sales Breakers Future Treatments - Early Stage Market Dynamics - Winners and Losers Key launches to 2011 Competitor Ratio Analysis - Products Competitor Ratio Analysis - Companies Companies and Drugs Mentioned --Acomplia (sanofi-aventis) --AERx iDMS (NovoNordisk/Paradigm) --Arxxant (Eli Lilly Eli Lilly can refer to:
--APD356 (Arena Pharmaceuticals) --AVE-0010 (sanofi-aventis) --Byetta (Eli Lilly/Amylin) --Exubera (Pfizer) --Galida (AstraZeneca) --Galvus (Novartis) --Januvia (Merck & Co) --Liraglutide (Novo Nordisk Wikipedia is not the place for advertisement or self-advertising. Novo Nordisk (, NYSE: NVO) manufactures and markets pharmaceutical products and services. Founded in Denmark in 1923, the company has since become a world leader in diabetes care with the broadest ) --Naveglitazar (Eli Lilly) --Pargluva (BMS BMS abbr. Bachelor of Marine Science ) --Saxagliptin- Metabolism (Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were ) --Soraprazan (Altana) --Suloxdexide (Keryx) --TAK-390MR (Takeda) For more information visit http://www.researchandmarkets.com/reports/c37789 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion